Seven Eight Capital, LP Argenx Se Transaction History

Seven Eight Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$356.95 - $413.29 $442,974 - $512,892	1,241 Added 66.4%	3,110 $1.22 Million
Q4 2023 Feb 13, 2024	BUY	$338.91 - $506.01 $633,422 - $945,732	1,869 New	1,869 $711,000
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $237,061 - $299,761	-1,100 Closed	0 $0
Q2 2020 Aug 06, 2020	BUY	$127.44 - $232.72 $140,184 - $255,992	1,100 New	1,100 $248,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.